IgG4-related disease: Is rituximab the best therapeutic strategy for cases refractory to conventional therapy? Results of a systematic review Laura Betancur-Vásquez; Daniel Gonzalez-Hurtado; Daniela Arango-Isaza; Adriana Rojas-Villarraga; Deicy Hernandez-Parra; Samuel Carmona; J.C. Díaz-Coronado;

Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023 Carlos Abud-Mendoza; Francisco Javier Aceves-Ávila; César Alejandro Arce-Salinas; José Álvarez Nemegyei; Leonor Barile-Fabris; Sergio Durán-Barragán; Diana Elsa Flores-Alvarado; Eufrates Hernández-Núñez; Fedra Irazoque-Palazuelos; José Francisco Moctezuma-Ríos; Virginia Pascual-Ramos; Margarita Portela-Hernández; Luis Humberto Silveira; Lilia Andrade-Ortega; Ana Barrera-Vargas; Sandra Carrillo-Vázquez; Zully Castro-Colin; Enrique Cuevas-Orta; Luis Felipe Flores-Suárez; Guillermo Arturo Guaracha-Basáñez; María Fernanda Hernández-Cabrera; Iván de Jesús Hernández-Galarza; David Alejandro Herrera-vanOostdam; Adriana Concepción Lobato-Belmonte; Laura Aline Martínez-Martínez; Marco Ulises Martínez-Martínez; Gabriel Medrano-Ramírez; Francisco Javier Merayo-Chalico; Graciela Meza-López y Olguín; Francisco Olan; Genaro Peña-Santos; César Ramos-Remus; Greta Reyes-Cordero; Vijaya Rivera-Terán; Jorge Rojas-Serrano; Griselda Serna-Peña; Sandra Sicsik-Ayala; César Armando Sifuentes-Cantú; David Vega-Morales; Pablo Villaseñor-Ovies; Daniel Xibillé-Friedmann; César Pacheco-Tena;

Hypertrophic pachymeningitis due to IgG4-related disease (RD-IgG4). A case report Paira Sergio; Reibaldi Alejandro; Froullet Cristian;